^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)

    i
    Other names: UGT1A7, UDP Glucuronosyltransferase Family 1 Member A7, UGT1G, UDP Glycosyltransferase 1 Family, Polypeptide A7, UDP-Glucuronosyltransferase 1A7, UDP-Glucuronosyltransferase 1-7, UDP-Glucuronosyltransferase 1-G, UDPGT 1-7, UGT1-07, UGT-1G, UGT1.7, GNT1, UGT1, UDP Glucuronosyltransferase 1 Family, Polypeptide A7, UDP-Glucuronosyltransferase 1 Family Polypeptide A7s, Bilirubin-Specific UDPGT Isozyme 1, UDP-Glucuronosyltransferase 1-1, UDP-Glucuronosyltransferase 1-A, UDP-Glucuronosyltransferase 1A1, UGT1-01, HUG-BR1, UGT-1A, UGT1.1, UGT1A1, UGT1*7, UDPGT, UGT1A
    Associations

    News

    Trials
    1m
    High Risk of Drug-Drug Interactions Caused by Pexidartinib via UDP-Glucuronosyltransferases Inhibition. (PubMed, Chem Res Toxicol)
    The results of in vitro-in vivo extrapolation (IVIVE) indicated that coadministration of pexidartinib at a clinically approved dose (400 mg twice daily) with the drugs primarily cleared by UGT1A1, UGT1A6, UGT1A7, UGT1A9, and UGT2B15 would result in a higher risk of DDI. In summary, our results provide useful information for the mechanism underlying pexidartinib-induced hepatotoxicity and clinical safe medication of pexidartinib.
    Journal
    |
    UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    Turalio (pexidartinib)
    4ms
    Influence of genetic polymorphisms on gefitinib pharmacokinetics and adverse drug reactions in non-small cell lung cancer patients. (PubMed, Cancer Metastasis Rev)
    Hence, further comprehensive research is essential to examine these genetic variants across different ethnic groups, monitor the drug-drug interactions, and study the phenoconversion to draw definitive conclusions about the pharmacokinetics of gefitinib. This could lead to the development and implementation of a genotyping-based approach for gefitinib dosage optimization in clinical settings.
    PK/PD data • Review • Journal • Adverse drug reaction
    |
    EGFR (Epidermal growth factor receptor) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • FOXO3 (Forkhead box O3) • CYP3A4 (Cytochrome P450, family 3, subfamily A, polypeptide 4) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    |
    gefitinib
    8ms
    High burden of variants of uncertain significance in early-onset colorectal cancer among indigenous African patients: a call for global research equity in cancer genetics. (PubMed, Mol Biol Rep)
    Our findings reveal a high burden of potentially pathogenic VUSs in indigenous African patients with eoCRC, reflecting both unique genetic architecture and a critical gap in global genomic equity. These variants may contribute to future variant reclassification and improved understanding of CRC predisposition in African populations. This study underscores the urgent need for population-specific genomic research and the development of inclusive variant databases to support accurate diagnosis and personalised care.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • NOTCH1 (Notch 1) • ASXL1 (ASXL Transcriptional Regulator 1) • WT1 (WT1 Transcription Factor) • NOTCH2 (Notch 2) • CHEK2 (Checkpoint kinase 2) • FAT1 (FAT atypical cadherin 1) • RAD51B (RAD51 Paralog B) • RAD54L (DNA Repair And Recombination Protein RAD54) • ERCC4 (ERCC Excision Repair 4, Endonuclease Catalytic Subunit) • IR (Insulin receptor) • MITF (Melanocyte Inducing Transcription Factor) • PYCR1 (Pyrroline-5-Carboxylate Reductase 1) • RECQL (RecQ Like Helicase) • LZTR1 (Leucine Zipper Like Transcription Regulator 1) • RASA1 (RAS P21 Protein Activator 1) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    12ms
    Pharmacogenomics-Based Detection of Variants Involved in Pain, Anti-inflammatory and Immunomodulating Agents Pathways by Whole Exome Sequencing and Deep in Silico Investigations Revealed Novel Chemical Carcinogenesis and Cancer Risks. (PubMed, Iran J Med Sci)
    Conclusively, six potentially actionable variants including rs1695 (GSTP1), rs628031 (SLC22A1), rs17863778 (UGT1A7), rs16947 (CYP2D6), rs2257401 (CYP3A7), and rs2515641 (CYP2E1) had the most deviations among Iranians, compared with the reference genome, which should be genotyped for drug prescribing. Remarkably, PPIs, GMIs, and EA revealed potential risks of carcinogenesis and cancer phenotypes resulting from PAIma pathways genes.
    Journal
    |
    GSTP1 (Glutathione S-transferase pi 1) • SLC22A1 (Solute Carrier Family 22 Member 1) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    over1year
    Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by darolutamide: prediction of in vivo drug-drug interactions. (PubMed, Chem Biol Interact)
    In particular, it also potently inhibited SN-38, the active metabolite of irinotecan, glucuronidation in HLMs with an IC50 value of 3.84 ± 0.46 μM. The prediction results showed that darolutamide may increase the risk of DDIs when administered in combination with substrates of UGT1A1, UGT1A7, or UGT2B15. Therefore, the combined administration of darolutamide and drugs metabolized by the above UGTs should be used with caution to avoid the occurrence of potential DDIs.
    Preclinical • Journal
    |
    UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    UGT1A1*1*1
    |
    irinotecan • Nubeqa (darolutamide)
    over1year
    UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment. (PubMed, Cancer Gene Ther)
    Low UGT1A7 expression plays an important role in EMT and contributes to trastuzumab resistance. UGT1A7 has the potential to be developed as a biomarker for identifying patients who are resistant to trastuzumab treatment.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5) • SNAI1 (Snail Family Transcriptional Repressor 1) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    |
    Herceptin (trastuzumab)
    almost2years
    Inhibition of Human UDP-Glucuronosyltransferase Enzyme by Entrectinib: Implications for Drug-Drug Interactions. (PubMed, Chem Biol Interact)
    Furthermore, the results from quantitative prediction research suggested that the combination of entrectinib at 600 mg/day with substrates primarily metabolized by hepatic UGT2B15 or intestinal UGT1A7 and UGT1A8 might cause clinical DDIs. Thus, special attention should be paid to avoid adverse reactions induced by DDIs when co-administration of entrectinib and drugs metabolized by UGTs.
    Journal
    |
    UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT1A8 (UDP Glucuronosyltransferase Family 1 Member A8)
    |
    Rozlytrek (entrectinib)
    almost2years
    Identification of ADME genes polymorphic variants linked to trastuzumab-induced cardiotoxicity in breast cancer patients: Case series of mono-institutional experience. (PubMed, Biomed Pharmacother)
    Real-world TIC incidence is higher compared to randomized clinical trials and biomarkers with potential predictive value aren't available. Our preliminary data, as proof of concept, could suggest a predictive role of pharmacogenomic approach in the identification of cardiotoxicity risk biomarkers for anti-HER2 treatment.
    Clinical • Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • SLC22A1 (Solute Carrier Family 22 Member 1) • CYP3A5 (Cytochrome P450 Family 3 Subfamily A Member 5) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15)
    |
    UGT1A1*1*1
    |
    Herceptin (trastuzumab)
    almost2years
    The Active Glucuronide Metabolite of the Brain Protectant IMM-H004 with Poor Blood-Brain Barrier Permeability Demonstrates a High Partition in the Rat Brain via Multiple Mechanisms. (PubMed, Pharmaceutics)
    The active glucuronide metabolite of the brain protectant IMM-H004 with poor blood-brain barrier permeability demonstrates a high partition in the rat brain via multiple mechanisms, and our findings deepen the understanding of the mechanisms underlying the blood-brain barrier metabolism and transport of active glucuronide conjugates.
    Preclinical • Journal
    |
    SLCO2B1 (Solute Carrier Organic Anion Transporter Family Member 2B1) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    over2years
    Potential risk of drug-drug interactions of ponatinib via inhibition against human UDP-glucuronosyltransferases. (PubMed, Toxicol In Vitro)
    Our study presented that ponatinib showed a broad-spectrum inhibition against UGTs. Particularly, ponatinib exhibited potent inhibitory effects towards UGT1A7, UGT1A1, and UGT1A9 with IC values of 0.37, 0.41, and 0.89 μM, respectively, which might lead to clinically significant DDI.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    |
    UGT1A1*1*1
    |
    Iclusig (ponatinib)
    over2years
    Drug-drug interaction potentials of tucatinib inhibition of human UDP-glucuronosyltransferases. (PubMed, Chem Biol Interact)
    The quantitative prediction of DDIs risk indicated that the co-administration of tucatinib with drugs mainly metabolized by hepatic or intestinal UGTs (UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, UGT1A10, UGT2B15 and UGT2B17) might result in potential DDIs risk through inhibition of glucuronidation. More attention should be paid to the influence of tucatinib on UGTs in liver and intestine to avoid unnecessary clinical DDIs risk.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • UGT1A9 (UDP Glucuronosyltransferase Family 1 Member A9) • UGT1A6 (UDP Glucuronosyltransferase Family 1 Member A6) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7) • UGT2B15 (UDP Glucuronosyltransferase Family 2 Member B15) • UGT2B17 (UDP Glucuronosyltransferase Family 2 Member B17) • UGT1A10 (UDP Glucuronosyltransferase Family 1 Member A10) • UGT1A3 (UDP Glucuronosyltransferase Family 1 Member A3) • UGT1A8 (UDP Glucuronosyltransferase Family 1 Member A8)
    |
    HER-2 positive • UGT1A1*1*1
    |
    Tukysa (tucatinib)
    almost3years
    Characterization of Enzymes Involved in Nintedanib Metabolism in Humans. (PubMed, Drug Metab Dispos)
    Significance Statement To our knowledge, this is the first study to characterize the enzymes responsible for each step of nintedanib metabolism in the human body. We found that β-glucuronidase may contribute to BIBF1202-G deglucuronidation.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • UGT1A7 (UDP Glucuronosyltransferase Family 1 Member A7)
    |
    UGT1A1*28 • UGT1A1*1*1 • UGT1A1 wild-type
    |
    nintedanib